Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$8.36 +9.1%	$7.05	$5.47 ▼ $11.99	$159.01M	N/A	64,528 shs	58,818 shs
CYBN Cybin	$7.15 +3.3%	$7.68	$4.81 ▼ $13.88	$168.67M	0.68	320,405 shs	592,928 shs
GBIO Generation Bio	$6.45 +2.7%	$4.40	$3.00 ▼ $29.40	$42.30M	2.67	814,285 shs	78,248 shs
NKTX Nkarta	$2.37 +2.2%	$1.97	$1.31 ▼ $6.63	$164.78M	0.72	533,165 shs	746,326 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	+9.14%	+2.96%	+26.67%	-19.07%	-2.79%
CYBN Cybin	+3.32%	+1.27%	-7.86%	-4.28%	+1,837.67%
GBIO Generation Bio	+2.71%	+2.54%	+48.96%	+74.28%	-75.10%
NKTX Nkarta	+2.16%	+1.72%	+6.28%	+35.43%	-55.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	2.4484 of 5 stars	3.6	0.0	0.0	0.0	1.7	0.8	1.3
GBIO Generation Bio	3.2056 of 5 stars	3.3	3.0	0.0	0.0	1.5	3.3	1.3
NKTX Nkarta	2.0327 of 5 stars	3.5	0.0	0.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	145.22% Upside
CYBN Cybin	3.25	Buy	$85.00	1,088.81% Upside
GBIO Generation Bio	2.67	Moderate Buy	$10.67	65.37% Upside
NKTX Nkarta	3.00	Buy	$13.60	473.84% Upside

Current Analyst Ratings Breakdown

Latest GBIO, CYBN, ACTU, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/18/2025	GBIO Generation Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/14/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
8/13/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $7.00
8/13/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/13/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/18/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $70.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	($0.13) per share	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
GBIO Generation Bio	$21.23M	2.05	N/A	N/A	$8.03 per share	0.80
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	-19,736.59%	-281.83%	N/A
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
GBIO Generation Bio	-$131.67M	-$10.82	N/A	N/A	N/A	-341.12%	-91.07%	-33.65%	11/5/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.48	N/A	N/A	N/A	N/A	-27.74%	-22.38%	11/6/2025 (Estimated)

Latest GBIO, CYBN, ACTU, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACTU Actuate Therapeutics	-$0.19	-$0.30	-$0.11	-$0.30	N/A	N/A
8/12/2025	Q2 2025	GBIO Generation Bio	-$2.80	-$3.12	-$0.32	-$3.12	$2.51 million	$0.77 million
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.73	0.46
CYBN Cybin	N/A	24.24	24.24
GBIO Generation Bio	N/A	7.51	7.51
NKTX Nkarta	N/A	15.67	15.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
CYBN Cybin	17.94%
GBIO Generation Bio	95.22%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
CYBN Cybin	15.00%
GBIO Generation Bio	21.80%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	20.75 million	6.36 million	N/A
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
GBIO Generation Bio	150	6.74 million	5.27 million	Optionable
NKTX Nkarta	140	71.03 million	65.06 million	Optionable

GBIO, CYBN, ACTU, and NKTX Headlines

Recent News About These Companies

Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by Wall Street Zen

August 19, 2025 | americanbankingnews.com

Equities Analysts Issue Forecasts for Nkarta Q3 Earnings

August 17, 2025 | marketbeat.com

Equities Analysts Set Expectations for Nkarta Q3 Earnings

August 17, 2025 | marketbeat.com

Wall Street Zen Upgrades Nkarta (NASDAQ:NKTX) to "Hold"

August 17, 2025 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for Nkarta Earnings

August 17, 2025 | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Given New $12.00 Price Target at Stifel Nicolaus

August 16, 2025 | marketbeat.com

Stifel Nicolaus Issues Pessimistic Forecast for Nkarta (NASDAQ:NKTX) Stock Price

August 16, 2025 | americanbankingnews.com

Leerink Partnrs Brokers Boost Earnings Estimates for Nkarta

August 16, 2025 | americanbankingnews.com

Nkarta (NASDAQ:NKTX) Receives Buy Rating from Needham & Company LLC

August 15, 2025 | marketbeat.com

Needham & Company LLC Reiterates "Buy" Rating for Nkarta (NASDAQ:NKTX)

August 15, 2025 | americanbankingnews.com

Nkarta price target lowered to $12 from $14 at Stifel

August 15, 2025 | msn.com

Nkarta (NASDAQ:NKTX) Announces Earnings Results, Beats Estimates By $0.06 EPS

August 14, 2025 | marketbeat.com

Nkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 13, 2025 | finanznachrichten.de

Nkarta, Inc. Reports Q2 2025 Financial Results

August 12, 2025 | tipranks.com

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

August 12, 2025 | globenewswire.com

Nkarta (NKTX) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Monaco Asset Management SAM Invests $1.50 Million in Nkarta, Inc. (NASDAQ:NKTX)

July 31, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

July 30, 2025 | marketbeat.com

Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series

July 23, 2025 | tmcnet.com

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

July 23, 2025 | globenewswire.com

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

July 22, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GBIO, CYBN, ACTU, and NKTX Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$8.36 +0.70 (+9.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.40 +0.04 (+0.54%)

As of 08/22/2025 04:10 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Cybin NYSE:CYBN

$7.15 +0.23 (+3.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.16 +0.01 (+0.21%)

As of 08/22/2025 07:57 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Generation Bio NASDAQ:GBIO

$6.45 +0.17 (+2.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.54 +0.09 (+1.32%)

As of 08/22/2025 07:17 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$2.37 +0.05 (+2.16%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.05 (+2.15%)

As of 08/22/2025 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time